Peter Schmid

Peter Schmid is Professor of Cancer Medicin and Lead of Centre for Experimental Cancer Medicine at Barts Cancer Institute, London. He also leads the academic breast cancer programme at St. Bartholomew’s Hospital and BCI.

MEDtalks

Addition of Pembrolizumab to Standard Chemotherapy Patients with Early-Stage Triple-Negative Breast Cancer Has the Potential for a New Standard of Care

september 2024 / Peter Schmid

Bröstcancer ESMO24

Pembrolizumab + Chemotherapy: a New Standard of Carefor Triple-Negative Breast Cancer

oktober 2023 / Peter Schmid

Bröstcancer ESMO23 3:25